title: Production of monoclonal antibodies in plants for cancer immunotherapy.
abstract: Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants can be propagated indefinitely, providing cheap biomass production on a large scale in controlled conditions. Thus, recent studies have shown the successful development of plant systems for the production of mAbs for cancer immunotherapy. However, their several limitations have to be resolved for efficient antibody production in plants.
authors.affiliation: Major of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon National University, Incheon 406-840, Republic of Korea.
authors.forename: Ghislain
authors.initials: G
authors.lastname: Moussavou
authors.affiliation: Department of Medicine, College of Medicine, Chung-Ang University, Seoul 156-756, Republic of Korea.
authors.forename: Kisung
authors.initials: K
authors.lastname: Ko
authors.affiliation: Department of Medicine, College of Medicine, Chung-Ang University, Seoul 156-756, Republic of Korea.
authors.forename: Jeong-Hwan
authors.initials: JH
authors.lastname: Lee
authors.affiliation: Department of Biological Science, College of Natural Sciences, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea ; Institute for Glycoscience, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea.
authors.forename: Young-Kug
authors.initials: YK
authors.lastname: Choo
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D030821:Plants, Genetically Modified / Q000235:genetics / Q000276:immunology*; D015202:Protein Engineering / Q000379:methods; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome; D059016:Tumor Microenvironment
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D011994:Recombinant Proteins